Evidence map›Paper›PMID 21131602›Full record

ArticleInternational journal of toxicology2011

Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells.

Rishi B Patel, Sainath R Kotha, Shariq I Sherwani, Sean M Sliman, Travis O Gurney, Brooke Loar, Susan O'Connor Butler, Andrew J Morris, Clay B Marsh, Narasimham L Parinandi

Open access · greenAbstract read
In one paragraph

Article in International journal of toxicology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Metabolic reprogramming of pulmonary fibrosis.Frontiers in pharmacology · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities.International journal of molecular sciences · 2016
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rishi B PatelLipid Signaling, Lipidomics, and Vasculotoxicity Laboratory, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, 43210, USA.
Sainath R Kotha
Shariq I Sherwani
Sean M Sliman
Travis O Gurney
Brooke Loar
Susan O'Connor Butler
Andrew J Morris
Clay B Marsh
Narasimham L Parinandi
The Ohio State University · USUniversity of Kentucky · US

Funding

Intermittent hypoxia, adiponectin, and insulin resistance in cardiovascular riskR01HL093463 · NHLBI · OHIO STATE UNIVERSITY · PI MAGALANG, ULYSSES J, PARINANDI, NARASIMHAM LAXMI · 2010 to 2013
$1.5M
Thermo/Finnigan TSQ AM Triple Stage Quadrupole Mass SpectrometerS10RR024598 · NCRR · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2008 to 2008
$493k
NCRR NIH HHS S10 RR024598NHLBI NIH HHS HL093463NHLBI NIH HHS R01 HL093463
6 · The paper itself

Abstract

The mechanisms of lung microvascular complications and pulmonary hypertension known to be associated with idiopathic pulmonary fibrosis (IPF), a debilitating lung disease, are not known. Therefore, we investigated whether bleomycin, the widely used experimental IPF inducer, would be capable of activating phospholipase D (PLD) and generating the bioactive lipid signal-mediator phosphatidic acid (PA) in our established bovine lung microvascular endothelial cell (BLMVEC) model. Our results revealed that bleomycin induced the activation of PLD and generation of PA in a dose-dependent (5, 10, and 100 µg) and time-dependent (2-12 hours) fashion that were significantly attenuated by the PLD-specific inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI). PLD activation and PA generation induced by bleomycin (5 µg) were significantly attenuated by the thiol protectant (N-acetyl-L-cysteine), antioxidants, and iron chelators suggesting the role of reactive oxygen species (ROS), lipid peroxidation, and iron therein. Furthermore, our study demonstrated the formation of ROS and loss of glutathione (GSH) in cells following bleomycin treatment, confirming oxidative stress as a key player in the bleomycin-induced PLD activation and PA generation in ECs. More noticeably, PLD activation and PA generation were observed to happen upstream of bleomycin-induced cytotoxicity in BLMVECs, which was protected by FIPI. This was also supported by our current findings that exposure of cells to exogenous PA led to internalization of PA and cytotoxicity in BLMVECs. For the first time, this study revealed novel mechanism of the bleomycin-induced redox-sensitive activation of PLD that led to the generation of PA, which was capable of inducing lung EC cytotoxicity, thus suggesting possible bioactive lipid-signaling mechanism/mechanisms of microvascular disorders encountered in IPF.

Indexed as

Antibiotics, AntineoplasticBleomycinCell SurvivalDomperidoneDose-Response Relationship, DrugEndothelium, VascularEnzyme ActivationIdiopathic Pulmonary FibrosisIndolesLungMicrovesselsOxidation-ReductionOxidative StressPhosphatidic AcidsPhospholipase DReactive Oxygen Species5-fluoro-2-indolyldeschlorohalopemideAntibiotics, AntineoplasticBleomycinDomperidoneIndolesPhosphatidic AcidsPhospholipase DReactive Oxygen Species

Identifiers

PMID21131602
PMCPMC3503147
OpenAlexW1979629832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.